Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
All venous thrombosis clinical trials
|
|
Treatments
Studied treatment |
LMWH, 200 IU/kg qd followed by Dalteparin 150 IU/kg qd
|
Control treatment |
LMWH, 200 IU/kg qd followed by Warfarin target INR 2-3
|
Patients
Patients |
patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography |
Baseline characteristics |
objective DVT diagnosis |
Venography/CUS |
objective PR diagnosis |
HCT/PA/VPLS |
cancer (%) |
100% |
Outcome assessment blinded |
Yes |
|
Method and design
Randomized effectives |
336 / 336 (studied vs. control) |
Blinding |
open |
Follow-up duration |
6 mo |
Number of centre |
multicenter |
Primary endpoint |
recurrent thrombosis |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
VTE during active anticoagulant treatment
27 / 336
53 / 336
0,51 [0,33;0,79]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Studied treat. |
Control treat. |
VTE during active anticoagulant treatment
|
27 / 336 (8,0%) |
53 / 336 (15,8%) |
0,51 |
[0,33;0,79] |
|
The primary endpoint (if exists) appears in blod characters
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
VTE during active anticoagulant treatment |
8,04% |
15,77% |
-77,4‰
|
Reference(s)
-
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer..
N Engl J Med 2003;349:146-53
Pubmed
|
Hubmed
| Fulltext
-
Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN.
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism..
J Clin Oncol 2005;23:2123-9
Pubmed
|
Hubmed
| Fulltext
|